首页 | 本学科首页   官方微博 | 高级检索  
     

pVVP3IL-18HN核酸疫苗的构建及其对喉癌细胞杀伤作用的研究
引用本文:管国芳,金宁一,米志强,李霄,连海,金春顺,孙丽丽,文连姬. pVVP3IL-18HN核酸疫苗的构建及其对喉癌细胞杀伤作用的研究[J]. 中华耳鼻咽喉头颈外科杂志, 2005, 40(8): 566-570
作者姓名:管国芳  金宁一  米志强  李霄  连海  金春顺  孙丽丽  文连姬
作者单位:1. 130041,长春,吉林大学白求恩医学部第二临床医院耳鼻咽喉科
2. 军事医学科学院全军基因工程重点实验室
基金项目:“973”规划(G199011902)和自然科学基金重大项目(39893290-4-3)
摘    要:目的通过构建共表达凋亡素基因、新城疫病毒HN基因和白介素18(interleukin-18,IL-18)基因的核酸疫苗,观察联合应用此三种基因对喉癌细胞的杀伤效应。方法在真核表达质粒pVAX1中的CMV启动子下游插入凋亡素基因和含有IL-18HN嵌合基因并携带IRES启动子的基因片段,构建能同时表达三种基因的真核表达质粒pVVP3IL-18HN,经RT—PCR、间接免疫荧光和Western—blot法检测外源基因的表达。采用脂质体介导法将构建的重组质粒pVVP3IL-18HN体外转染Hep-2细胞,运用MTT法检测不同质粒浓度、不同作用时间,该重组质粒对喉癌细胞Hep-2的杀伤率。结果pVVP3IL-18HN可有效杀伤喉癌细胞,且在作用72h、质粒浓度为20μg/ml时杀伤率最高,达61.9%。结论重组质粒pVVP3IL-18HN能有效杀伤Hep-2细胞,可用于喉癌的治疗和研究。

关 键 词:pVVP3IL-18HN 核酸疫苗 喉癌 肿瘤细胞 杀伤作用
收稿时间:2005-01-10
修稿时间:2005-01-10

Construction of the nucleic vaccine pVVP3IL-18HN and its antitumor effect on human laryngeal carcinoma
GUAN Guo-fang,JIN Ning-yi,MI Zhi-qiang,LI Xiao,LIAN Hai,Jin Chun-shun,SUN Li-li,WEN Lian-ji. Construction of the nucleic vaccine pVVP3IL-18HN and its antitumor effect on human laryngeal carcinoma[J]. Chinese journal of otorhinolaryngology head and neck surgery, 2005, 40(8): 566-570
Authors:GUAN Guo-fang  JIN Ning-yi  MI Zhi-qiang  LI Xiao  LIAN Hai  Jin Chun-shun  SUN Li-li  WEN Lian-ji
Affiliation:Department of Otorhinolaryngology, The Second Hospital of Jilin University, Changchun 130041, China.
Abstract:OBJECTIVE: Nucleic vaccine of pVVP3IL-18HN expressing apoptin gene, Newcastle disease virus HN gene and IL-18 gene were constructed to observe the combinative antitumor effect of the above three genes. METHODS: Eukaryotic expression plasmid pVVP3IL-18HN was constructed by inserting apoptin gene and fragment comprising fused IL-18HN gene and IRES promoter into the downstream of CMV promoter of vector pVAX1. The expression of inserted gene was identified by RT-PCR, indirect immunofluorescence and Western-blot. The recombinant plasmid was introduced into Hep-2 cells by liposome, then suppression rate of Hep-2 of different time and different quantity was calculated according to MTT results. RESULT: The recombinant plasmid of pVVP3IL-18HN suppressed Hep-2 successfully and its suppression rate was up to 61.9% with 20 microg/ml, incubation of 72 hours. CONCLUSION: The nucleic vaccine construced pVVP3IL-18HN had antitumor effect on Hep-2. It may can be used to the therapy and research of laryngeal carcinoma.
Keywords:Vaccines, DNA   Laryngeal neoplasms   DNA, recombinant   Newcastle disease virus   Interleukin-18    Tumor cells, cultured
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号